Randomized clinical trial of imiquimod: An adjunct to treating cervical dysplasia

Deirdre R. Pachman, Debra L. Barton, Amy C. Clayton, Renee M. McGovern, John A. Jefferies, Paul J. Novotny, Jeff A Sloan, Charles Lawrence Loprinzi, Bobbie S. Gostout

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Human papillomavirus (HPV) infection is a major risk factor for cervical cancer. Imiquimod is a topical medication that enhances the immune response to HPV-induced genital warts. This study evaluated cervical application of imiquimod as an adjunct to standard treatment for cervical dysplasia. Fifty-six patients were randomized to standard excisional/ablative treatment vs applications of imiquimod followed by standard treatment. The primary endpoint was dysplasia recurrence within 2 years. There were no differences in dysplasia recurrence between the 2 groups. Treatment was well tolerated, with side effects being mild but significantly worse in women receiving imiquimod for, chills, fatigue, fever, headache, myalgias, and vaginal discharge. This trial does not support the hypothesis that imiquimod, as used in this trial, has an impact on recurrence of cervical dysplasia, but the adequacy of findings are limited by sample size. The trial does support the feasibility and acceptability of the use of imiquimod on the cervix.

Original languageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
Volume206
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

imiquimod
Uterine Cervical Dysplasia
Randomized Controlled Trials
Recurrence
Vaginal Discharge
Condylomata Acuminata
Chills
Papillomavirus Infections
Myalgia
Therapeutics
Cervix Uteri
Uterine Cervical Neoplasms
Sample Size
Fatigue
Headache
Fever

Keywords

  • cervical dysplasia
  • human papillomavirus
  • imiquimod
  • loop electrosurgical excision procedure

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Pachman, D. R., Barton, D. L., Clayton, A. C., McGovern, R. M., Jefferies, J. A., Novotny, P. J., ... Gostout, B. S. (2012). Randomized clinical trial of imiquimod: An adjunct to treating cervical dysplasia. American Journal of Obstetrics and Gynecology, 206(1). https://doi.org/10.1016/j.ajog.2011.06.105

Randomized clinical trial of imiquimod : An adjunct to treating cervical dysplasia. / Pachman, Deirdre R.; Barton, Debra L.; Clayton, Amy C.; McGovern, Renee M.; Jefferies, John A.; Novotny, Paul J.; Sloan, Jeff A; Loprinzi, Charles Lawrence; Gostout, Bobbie S.

In: American Journal of Obstetrics and Gynecology, Vol. 206, No. 1, 01.2012.

Research output: Contribution to journalArticle

Pachman, Deirdre R. ; Barton, Debra L. ; Clayton, Amy C. ; McGovern, Renee M. ; Jefferies, John A. ; Novotny, Paul J. ; Sloan, Jeff A ; Loprinzi, Charles Lawrence ; Gostout, Bobbie S. / Randomized clinical trial of imiquimod : An adjunct to treating cervical dysplasia. In: American Journal of Obstetrics and Gynecology. 2012 ; Vol. 206, No. 1.
@article{7d2e655625354755bf693c2e2ceadd2b,
title = "Randomized clinical trial of imiquimod: An adjunct to treating cervical dysplasia",
abstract = "Human papillomavirus (HPV) infection is a major risk factor for cervical cancer. Imiquimod is a topical medication that enhances the immune response to HPV-induced genital warts. This study evaluated cervical application of imiquimod as an adjunct to standard treatment for cervical dysplasia. Fifty-six patients were randomized to standard excisional/ablative treatment vs applications of imiquimod followed by standard treatment. The primary endpoint was dysplasia recurrence within 2 years. There were no differences in dysplasia recurrence between the 2 groups. Treatment was well tolerated, with side effects being mild but significantly worse in women receiving imiquimod for, chills, fatigue, fever, headache, myalgias, and vaginal discharge. This trial does not support the hypothesis that imiquimod, as used in this trial, has an impact on recurrence of cervical dysplasia, but the adequacy of findings are limited by sample size. The trial does support the feasibility and acceptability of the use of imiquimod on the cervix.",
keywords = "cervical dysplasia, human papillomavirus, imiquimod, loop electrosurgical excision procedure",
author = "Pachman, {Deirdre R.} and Barton, {Debra L.} and Clayton, {Amy C.} and McGovern, {Renee M.} and Jefferies, {John A.} and Novotny, {Paul J.} and Sloan, {Jeff A} and Loprinzi, {Charles Lawrence} and Gostout, {Bobbie S.}",
year = "2012",
month = "1",
doi = "10.1016/j.ajog.2011.06.105",
language = "English (US)",
volume = "206",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Randomized clinical trial of imiquimod

T2 - An adjunct to treating cervical dysplasia

AU - Pachman, Deirdre R.

AU - Barton, Debra L.

AU - Clayton, Amy C.

AU - McGovern, Renee M.

AU - Jefferies, John A.

AU - Novotny, Paul J.

AU - Sloan, Jeff A

AU - Loprinzi, Charles Lawrence

AU - Gostout, Bobbie S.

PY - 2012/1

Y1 - 2012/1

N2 - Human papillomavirus (HPV) infection is a major risk factor for cervical cancer. Imiquimod is a topical medication that enhances the immune response to HPV-induced genital warts. This study evaluated cervical application of imiquimod as an adjunct to standard treatment for cervical dysplasia. Fifty-six patients were randomized to standard excisional/ablative treatment vs applications of imiquimod followed by standard treatment. The primary endpoint was dysplasia recurrence within 2 years. There were no differences in dysplasia recurrence between the 2 groups. Treatment was well tolerated, with side effects being mild but significantly worse in women receiving imiquimod for, chills, fatigue, fever, headache, myalgias, and vaginal discharge. This trial does not support the hypothesis that imiquimod, as used in this trial, has an impact on recurrence of cervical dysplasia, but the adequacy of findings are limited by sample size. The trial does support the feasibility and acceptability of the use of imiquimod on the cervix.

AB - Human papillomavirus (HPV) infection is a major risk factor for cervical cancer. Imiquimod is a topical medication that enhances the immune response to HPV-induced genital warts. This study evaluated cervical application of imiquimod as an adjunct to standard treatment for cervical dysplasia. Fifty-six patients were randomized to standard excisional/ablative treatment vs applications of imiquimod followed by standard treatment. The primary endpoint was dysplasia recurrence within 2 years. There were no differences in dysplasia recurrence between the 2 groups. Treatment was well tolerated, with side effects being mild but significantly worse in women receiving imiquimod for, chills, fatigue, fever, headache, myalgias, and vaginal discharge. This trial does not support the hypothesis that imiquimod, as used in this trial, has an impact on recurrence of cervical dysplasia, but the adequacy of findings are limited by sample size. The trial does support the feasibility and acceptability of the use of imiquimod on the cervix.

KW - cervical dysplasia

KW - human papillomavirus

KW - imiquimod

KW - loop electrosurgical excision procedure

UR - http://www.scopus.com/inward/record.url?scp=84455191837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84455191837&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2011.06.105

DO - 10.1016/j.ajog.2011.06.105

M3 - Article

C2 - 21907959

AN - SCOPUS:84455191837

VL - 206

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1

ER -